The Australian Technical Advisory Group on Immunisation (ATAGI) has updated their recommendation to allow for the inclusion of the XBB 1.5 COVID-19 vaccines in the National COVID-19 Vaccine Program, this aligns with the current vaccination eligibility criteria.
Effective as of the 11th of December, monovalent Omicron XBB.1.5 vaccines are the preferred option for children aged 5 years or older and adults in need of primary or additional doses, for more information refer to the Australian Immunisation Handbook.
Note individuals who have already received the recommended 2023 doses of the COVID-19 vaccine are currently advised against seeking additional doses or re-vaccination with an XBB.1.5 vaccine.
COVID-19 still a risk this holiday season?
The recent surge in COVID-19 cases across Australia since November 2023 serves as a reminder that the virus remains a significant health risk. This is especially pertinent as we approach the Christmas/New Year holiday period, which has historically seen with an uptick in COVID-19 cases.
ATAGI is highlighting the heightened risk faced by individuals living with disabilities and emphasizing the critical role of vaccination and adherence to COVID-safe practices play in preventing serious illness.
In response to the current situation, ATAGI recommends that individuals over 18 who have a disability with significant or complex needs receive at least one booster dose in 2023. Additionally, all individuals yet to receive their recommended 2023 doses are encouraged to do so promptly. A summary of the ATAGI recommended COVID-19 vaccine doses is available on the Department of Health and Aged Care website.
Some vaccination services can visit people at home if they cannot travel to the service.
To book an appointment, go to the service finder or the Disability Gateway.
